## Carlo Merkel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7269400/publications.pdf

Version: 2024-02-01

66315 76872 5,839 109 42 74 citations h-index g-index papers 112 112 112 3871 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations. Digestive and Liver Disease, 2021, 53, 1468-1475.	0.4	12
2	Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE). Liver International, 2021, 41, 1070-1082.	1.9	15
3	Liver Fibrosis and Steatosis in Alström Syndrome: A Genetic Model for Metabolic Syndrome. Diagnostics, 2021, 11, 797.	1.3	9
4	Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy. Digestive and Liver Disease, 2020, 52, 235-236.	0.4	2
5	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2020, 18, 313-327.e6.	2.4	74
6	Training of Italian emergency medicine residents in prehospital emergency medicine: state of the art and perspectives of improvement. Internal and Emergency Medicine, 2020, 15, 519-522.	1.0	1
7	The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology, 2017, 66, 198-208.	3.6	135
8	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57
9	Introduction: Prevention of Decompensation Versus Prevention of First Bleeding., 2016,, 195-204.		0
10	Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELDâ€EEG. Liver International, 2015, 35, 58-64.	1.9	40
11	Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified <scp>EEG</scp> study. Liver International, 2015, 35, 1524-1532.	1.9	19
12	Cognitive impairment and electroencephalographic alterations before and after liver transplantation: What is reversible?. Liver Transplantation, 2014, 20, 977-986.	1.3	63
13	The Influence of Environmental Factors on Sleep Quality in Hospitalized Medical Patients. Frontiers in Neurology, 2014, 5, 267.	1.1	47
14	Sleep-wake abnormalities in patients with cirrhosis. Hepatology, 2014, 59, 705-712.	3.6	83
15	Covert Hepatic Encephalopathy: Does the Mini-Mental State Examination Help?. Journal of Clinical and Experimental Hepatology, 2014, 4, 89-93.	0.4	12
16	Cost-effectiveness analysis of beta-blockersvsendoscopic surveillance in patients with cirrhosis and small varices. World Journal of Gastroenterology, 2014, 20, 10464.	1.4	6
17	Covert hepatic encephalopathy: Agreement and predictive validity of different indices. World Journal of Gastroenterology, 2014, 20, 15756.	1.4	50
18	Prevention of the Formation and Growth of Esophageal Varices. , 2014, , 55-61.		1

#	Article	IF	CITATIONS
19	Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metabolic Brain Disease, 2013, 28, 239-243.	1.4	92
20	Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking. Metabolic Brain Disease, 2013, 28, 245-248.	1.4	37
21	Primary Prophylaxis of Bleeding from Esophageal Varices in Cirrhosis. Journal of Clinical and Experimental Hepatology, 2013, 3, 198-203.	0.4	2
22	Specificity of squamous cell carcinoma antigen (SCCA)â€IgM detection in patients with HCV infection and rheumatoid factor seropositivity. Journal of Medical Virology, 2013, 85, 1005-1008.	2.5	12
23	SERPINB3 is associated with longer survival in transgenic mice. Scientific Reports, 2013, 3, 3056.	1.6	12
24	Chronic Kidney Disease After Liver Transplantation. Transplantation, 2013, 95, 1148-1153.	0.5	35
25	Secondary prophylaxis in patients who have experienced portal hypertensive bleeding. Clinical Liver Disease, 2012, 1, 155-157.	1.0	0
26	Encephalopathy or hepatic encephalopathy?. Journal of Hepatology, 2012, 57, 928-929.	1.8	5
27	EASL Recognition Awardee 2012. Journal of Hepatology, 2012, 57, 239-240.	1.8	0
28	Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy. Digestive and Liver Disease, 2012, 44, 957-960.	0.4	31
29	Attention: Minimal hepatic encephalopathy and road accidents. Hepatology, 2012, 55, 985-987.	3.6	8
30	lgM-Linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease. PLoS ONE, 2012, 7, e40658.	1.1	22
31	Electroencephalography in Patients With Cirrhosis. Gastroenterology, 2011, 141, 1680-1689.e2.	0.6	47
32	A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2011, 9, 613-616.e1.	2.4	26
33	Hepatic venous pressure gradient measurement in clinical hepatology. Digestive and Liver Disease, 2011, 43, 762-767.	0.4	43
34	Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes!. European Journal of Internal Medicine, 2011, 22, 1-4.	1.0	14
35	Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats. Journal of Hepatology, 2011, 54, 258-264.	1.8	10
36	The Hunter and the Pianist. Journal of Clinical Gastroenterology, 2011, 45, 563-566.	1.1	11

#	Article	IF	CITATIONS
37	Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. Liver International, 2011, 31, 881-890.	1.9	21
38	Bright Times for Patients With Cirrhosis and Delayed Sleep Habits: A Case Report on the Beneficial Effect of Light Therapy. American Journal of Gastroenterology, 2011, 106, 2048-2049.	0.2	12
39	Reversal of hepatic myelopathy after liver transplantation: Fifteen plus one. Liver Transplantation, 2010, 16, 1336-1337.	1.3	24
40	SERPINB3 modulates TGF-β expression in chronic liver disease. Laboratory Investigation, 2010, 90, 1016-1023.	1.7	43
41	Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria. Journal of Hepatology, 2010, 52, 45-53.	1.8	26
42	A short cut to predict the clinical response to beta-blocker therapy in cirrhosis?. Journal of Hepatology, 2009, 51, 268-270.	1.8	2
43	Hepatitis C virus reinfection in liver transplant patients: Evaluation of liver damage progression with echo-color doppler. Liver Transplantation, 2008, 14, 616-624.	1.3	10
44	Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Molecular Aspects of Medicine, 2008, 29, 119-129.	2.7	48
45	Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. Journal of Hepatology, 2008, 48, S93-S103.	1.8	94
46	Carbon Monoxide-Mediated Activation of Large-Conductance Calcium-Activated Potassium Channels Contributes to Mesenteric Vasodilatation in Cirrhotic Rats. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 187-194.	1.3	62
47	Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: Analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters. Scandinavian Journal of Gastroenterology, 2007, 42, 256-262.	0.6	29
48	Acute Liver Rejection: Accuracy and Predictive Values of Doppler US Measurementsâ€"Initial Experience. Radiology, 2005, 235, 651-658.	3.6	30
49	varices in cirrhosis 1 1Members of the Gruppo Triveneto per l' pertensione Portale are as follows.  Steering committee: A. Gatta and C. Merkel (University of Padua, Padua, Italy); V. Donadon (General) Tj ETQq1 1 C  Tremolada (General Hospital of Belluno, Belluno, Italy); and G. Marin (General Hospital of Dolo, Dolo,) Ti ETOq1 1 C	0.0	207
50	The cirrhotic patient with no varices and with small varices. , 2004, , 271-276.		4
51	Nonselective $\hat{l}^2$ -blockers plus nitrates in portal hypertension: An open question. Hepatology, 2003, 37, 1254-1256.	3.6	6
52	Incidence and natural history of small esophageal varices in cirrhotic patients. Journal of Hepatology, 2003, 38, 266-272.	1.8	466
53	Endoscopic screening for esophageal varices in cirrhotic patients. Hepatology, 2002, 35, 501-502.	3.6	38
54	Change in portal flow after liver transplantation: Effect on hepatic arterial resistance indices and role of spleen size. Hepatology, 2002, 35, 601-608.	3.6	95

#	Article	IF	CITATIONS
55	Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: A controlled clinical trial. Liver Transplantation, 2002, 8, 527-534.	1.3	43
56	Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. Journal of Hepatology, 2001, 35, 37-45.	1.8	226
57	Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis. European Journal of Gastroenterology and Hepatology, 2001, 13, 163-169.	0.8	17
58	Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound in Medicine and Biology, 2001, 27, 901-907.	0.7	63
59	Nutrition and survival in patients with liver cirrhosis. Nutrition, 2001, 17, 445-450.	1.1	454
60	Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology, 2000, 31, 324-329.	3.6	127
61	The Hemodynamic Response to Medical Treatment of Portal Hypertension as a Predictor of Clinical Effectiveness in the Primary Prophylaxis of Variceal Bleeding in Cirrhosis. Hepatology, 2000, 32, 930-934.	3.6	224
62	Prognostic Indicators of Risk for First Variceal Bleeding in Cirrhosis: A Multicenter Study in 711 Patients To Validate and Improve The North Italian Endoscopic Club (Niec) Index. American Journal of Gastroenterology, 2000, 95, 2915-2920.	0.2	109
63	Natural History of Cirrhotic Patients With Small Esophageal Varices: A Prospective Study. American Journal of Gastroenterology, 2000, 95, 503-508.	0.2	99
64	Arterioportal Fistulas in Patients with Liver Cirrhosis: Usefulness of Color Doppler US for Screening. Radiology, 2000, 216, 738-743.	3.6	40
65	Visceral fistula as a complication of endoscopic treatment of esophageal and gastric varices using isobutyl-2-cyanoacrylate: report of two cases. Gastrointestinal Endoscopy, 2000, 52, 267-270.	0.5	42
66	Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology, 1999, 29, 1662-1667.	3.6	230
67	Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. European Journal of Gastroenterology and Hepatology, 1999, 11, 1221-1226.	0.8	12
68	Visual attention in cirrhotic patients: A study on covert visual attention orienting. Hepatology, 1998, 27, 1517-1523.	3.6	54
69	Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. Journal of Hepatology, 1998, 28, 115-121.	1.8	29
70	Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. Journal of Hepatology, 1998, 28, 622-630.	1.8	66
71	Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. Journal of Hepatology, 1997, 26, 305-311.	1.8	30
72	Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. Journal of Hepatology, 1997, 27, 986-992.	1.8	104

#	Article	IF	Citations
73	Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition, 1997, 13, $\nu$ -190.	1.1	59
74	Optimizing the time-frame for the definition of bleeding-related death after acute variceal bleeding in cirrhosis. European Journal of Gastroenterology and Hepatology, 1996, 8, 75-80.	0.8	1
75	Relationship between portal blood flow measured by image-directed doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. Journal of Clinical Ultrasound, 1995, 23, 297-303.	0.4	18
76	Interobserver and interquipment variability of echo-doppler examination of the portal vein: Effect of a cooperative training program. Hepatology, 1995, 21, 428-433.	3.6	152
77	Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology, 1995, 22, 808-813.	3.6	30
78	Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy. Metabolic Brain Disease, 1995, 10, 335-345.	1.4	13
79	Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: Relationships with portal hemodynamics. Gastroenterology, 1995, 108, 1152-1158.	0.6	141
80	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	3.6	100
81	Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology, 1994, 19, 628-634.	3.6	79
82	Circadian variation in the frequency of acute variceal bleeding in cirrhosis. Journal of Hepatology, 1994, 21, 912-913.	1.8	3
83	Adding beta-blockers to sclerotherapy in the prevention of variceal rebleeding: a meta-analysis assessment. Journal of Hepatology, 1994, 21, 918-919.	1.8	3
84	Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology, 1994, 19, 72-79.	3.6	5
85	Renal vasoconstriction in cirrhosis evaluated by duplex doppler ultrasonography. Hepatology, 1993, 17, 219-224.	3.6	100
86	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. Journal of Hepatology, 1993, 17, 56-61.	1.8	90
87	Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology, 1992, 102, 973-979.	0.6	177
88	Statistical methods for predicting variceal hemorrhage. Gastroenterology, 1992, 102, 1094-1095.	0.6	0
89	Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. Journal of Hepatology, 1992, 15, 299-303.	1.8	47
90	Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications. Hepatology, 1992, 16, 1389-1394.	3.6	26

#	Article	IF	Citations
91	Can we predict the first variceal bleeding in the individual patient with cirrhosis and esophageal varices?. Journal of Hepatology, 1991, 13, 378.	1.8	10
92	Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. Journal of Hepatology, 1991, 12, 124-125.	1.8	33
93	Hypophosphatemia and renal tubular dysfunction in alcoholics. Gastroenterology, 1991, 100, 502-512.	0.6	31
94	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Digestive Diseases and Sciences, 1991, 36, 1197-1203.	1.1	86
95	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	85
96	A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology, 1991, 14, 231-236.	3.6	9
97	Clinical Significance of Cholelithiasis in Patients with Decompensated Cirrhosis. Journal of Clinical Gastroenterology, 1990, 12, 538-541.	1.1	7
98	Clinical pharmacology of splanchnic circulation in cirrhosis. Pharmacological Research, 1990, 22, 235-252.	3.1	1
99	Substrate availability other than glucose in the brain during euglycemia and insulin-induced hypoglycemia in dogs. Metabolism: Clinical and Experimental, 1990, 39, 46-50.	1.5	20
100	Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans. Clinical Pharmacology and Therapeutics, 1988, 44, 211-216.	2.3	11
101	Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1103-1109.	1.1	43
102	d-Sorbitol clearance. Digestive Diseases and Sciences, 1988, 33, 1341-1341.	1.1	3
103	Value of Prealbumin Plasma Levels as Liver Test. Digestion, 1987, 37, 72-78.	1.2	22
104	Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. Journal of Hepatology, 1987, 4, 174-180.	1.8	55
105	The use of human albumin millimicrospheres tagged with 99mTc in the evaluation of the removal capacity of the reticuloendothelial system. European Journal of Nuclear Medicine and Molecular Imaging, 1987, 13, 254-7.	2.2	15
106	Redistribution of renal blood flow in patients with liver cirrhosis. Journal of Hepatology, 1986, 2, 253-261.	1.8	21
107	Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. American Heart Journal, 1984, 108, 1167-1172.	1.2	42
108	Renal Haemodynamics in Essential Hypertension Assessed by 133-Xenon Washout and Selective Renal Angiography. Angiology, 1982, 33, 818-824.	0.8	4

# Article IF Citations

Session 3: Prevention of the Formation of Varices (Pre-Primary Prophylaxis)., 0,, 103-151.

3